The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Characterization of Genome Integrity for Oversized Recombinant AAV Vector
Open accessAbstract
Application of recombinant adeno-associated virus (rAAV) in gene therapy has been limited by its packaging capacity. Recent studies suggested that rAAV could achieve persistent transgene expression beyond 4.7-kb packaging limit. To clarify the mechanism leading to transgene expression from oversized rAAV vector, we constructed a series of rAAV vectors with genomes ranging from 2.9 to 7.2 kb. A plasmid replication origin and an ampicillin-resistant marker were included in the vector to facilitate the recovery of circularized, post-transduction AAV genome. Southern dot-blot analysis and silver staining confirmed that rAAVs could be produced at varying vector size. However, the vector yields decreased approximately tenfold for oversized vectors as compared to regular ones. Alkaline Southern blot hybridization suggested that the packaged genomes for oversized vectors were truncated. In the cells transduced by the above vectors, circularized rAAV monomers could be rescued at 24 hours after infection. Few recovered AAV genomes were >5 kb regardless of the initial vector size. In mice receiving the above vectors, larger circularized rAAV genomes could be recovered for oversized vectors at day 21 after vector administration. Our studies suggested that the partially packaged rAAV sequences may complement each other to restore full expression cassette.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other studies [6-8] indicated that intact genomes were not, in fact, packaged in that case [3], and further suggested a strict size cutoff of 5.2 kb.”
From Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons (2014) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One limitation of rAAVs is that their genome-packaging capacity is only * 5kb.”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“However, the finding that AAV5 capsids could package intact genomes of up to 8.9 kb in length was not supported by further studies, which found that such genomes were truncated and that the packaging capacity of AAV was still limited to genomes substantially smaller than 8.9 kb. 30-32”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 906
Site-specific integration by adeno-associated virus.
Linden, R. M., Ward, P., Giraud, C., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11288 · Cited by 805
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Self-citationGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Grimm, D., & Kay, M. A. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 351
Samulski, R. J., Srivastava, A., Berns, K. I., & Muzyczka, N. (1983) · Cell · doi:10.1016/0092-8674(83)90342-2 · Cited by 297
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292
Hajjar, R. J., Zsebo, K. M., Deckelbaum, L. I., Thompson, C., Rudy, J., Yaroshinsky, A., Ly, H. Q., Kawase, Y., Wagner, K., Borow, K., et al. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.02.005 · Cited by 220
Large‐scale molecular characterization of adeno‐associated virus vector integration in mouse liver
Nakai, H., Wu, X., Fuess, S., Storm, T. A., Munroe, D., Montini, E., Burgess, S. M., Grompe, M., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3606-3614.2005 · Cited by 190
Self-citationIsolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver
Nakai, H., Iwaki, Y., Kay, M. A., & Couto, L. B. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5438-5447.1999 · Cited by 186
Self-citationYang, C., Xiao, X., Zhu, X., Ansardi, D. C., Epstein, N. D., Frey, M., Matera, A. G., & Samulski, R. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9231-9247.1997 · Cited by 178
New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors
Ferrari, F. K., Xiao, X., McCarty, D. M., & Samulski, R. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1295 · Cited by 112
Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K. A., Warrington, K. H., & Srivastava, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.088 · Cited by 108
Structural Analysis of Adeno-Associated Virus Transduction Circular Intermediates
Duan, D., Yan, Z., Yue, Y., & Engelhardt, J. F. (1999) · Virology · doi:10.1006/viro.1999.9821 · Cited by 100
Hermonat, P. L., Quirk, J. G., Bishop, B. M., & Han, L. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00311-6 · Cited by 98
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects
Hasbrouck, N. C., & High, K. A. (2008) · Gene Therapy · doi:10.1038/gt.2008.71 · Cited by 95
Duan, D., Sharma, P., Dudus, L., Zhang, Y., Şanlıoğlu, S., Yan, Z., Yue, Y., Ye, Y., Lester, R., Yang, J., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.161-169.1999 · Cited by 91
Li, W., Zhang, L., Johnson, J. S., Wu, Z., Grieger, J. C., Xiao, P., Drouin, L. M., Agbandje‐McKenna, M., Pickles, R. J., & Samulski, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.155 · Cited by 89
The Role of DNA-PKcs and Artemis in Opening Viral DNA Hairpin Termini in Various Tissues in Mice
Inagaki, K., Ma, C., Storm, T. A., Kay, M. A., & Nakai, H. (2007) · Journal of Virology · doi:10.1128/jvi.01225-07 · Cited by 70
Self-citationLack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D
Rodino‐Klapac, L. R., Lee, J.-S., Mulligan, R. C., Clark, K. R., & Mendell, J. R. (2008) · Neurology · doi:10.1212/01.wnl.0000306309.85301.e2 · Cited by 61
Cao, L., Liu, Y., During, M. J., & Xiao, W. (2000) · Journal of Virology · doi:10.1128/jvi.74.24.11456-11463.2000 · Cited by 56
Self-citationLu, H., Chen, L., Wang, J., Huack, B., Sarkar, R., Zhou, S., Xu, R. R., Ding, Q., Wang, X., Wang, H., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.0182 · Cited by 50
Self-citationChen, L., Zhu, F., Li, J., Lu, H., Jiang, H., Sarkar, R., Arruda, V. R., Wang, J., Zhao, J., Pierce, G. F., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300268 · Cited by 43
Self-citationNakai, H., Storm, T. A., Fuess, S., & Kay, M. (2003) · Human Gene Therapy · doi:10.1089/104303403765701169 · Cited by 35
Self-citationUpdate on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
High, K. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.466 · Cited by 32
Enhanced Factor VIII Heavy Chain for Gene Therapy of Hemophilia A
Chen, L., Lu, H., Wang, J., Sarkar, R., Yang, X. J., Wang, H., High, K. A., & Xiao, W. (2009) · Molecular Therapy · doi:10.1038/mt.2008.292 · Cited by 31
Self-citationReplication competent helper functions for recombinant AAV vector generation
Cao, L., During, M. J., & Xiao, W. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301710 · Cited by 26
Self-citationAAV Vectors, the Future Workhorse of Human Gene Therapy
Samulski, R. J. (2003) · Springer eBooks · doi:10.1007/978-3-662-05352-2_3 · Cited by 19
Asokan, A., & Samulski, R. J. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-158 · Cited by 11
Cited by
Sorted by citations
Optogenetics in neural systems
Yizhar, O., Fenno, L. E., Davidson, T. J., Mogri, M., & Deisseroth, K. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.004 · Cited by 1,881
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 384
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 382
Metadata
- Authors
- Dong, B., Nakai, H., & Xiao, W.
- Affiliations
- Temple University (US)
- University of Pittsburgh (US)
- Corresponding author
- Xiao, Weidong
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 18
- Issue
- 1
- Pages
- 87-92
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2803017
- OpenAlex
- W2049442129
- Cited by
- 230
- References
- 38
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 14 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 18 · 2019: 17 · 2018: 8 · 2017: 15 · 2016: 13 · 2015: 16 · 2014: 20 · 2013: 9 · 2012: 15
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL084381, HL080789, HL084381, R01HL080789)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- recombinant adeno-associated virus, genome stability, transgene expression, gene therapy vectors
- MeSH terms
- Dependovirus, Animals, Cell Line, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Genome, Viral, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
